Search

Search Constraints

You searched for: Author/Creator Elliott, Brian

Search Results

1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Issue 10306 (25th September 2021)

2. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Issue 12 (20th April 2023)

3. Hospital Career Structure. Issue 5608 (29th June 1968)

5. Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas. Issue 5 (27th September 2022)